Janssen ‘will continue endeavors to the Korean society’

through the provision of innovative pharmaceuticals and fostering talent

Janssen Korea holds press conference celebrating the 40th year of this establishment in Korea on the 23rd

Will contribute to Korean society through the provision of innovative pharmaceuticals, fostering talent, and open innovation

Cherry Huang, Managing Director of Janssen Korea, “Janssen has shown strengths in various therapeutic areas, and will seek cogrowth with the future Korean society.”

Janssen Korea held a press conference celebrating its 40th year of establishment at the Seoul Plaza Hotel on the 23rd

Janssen, which has succeeded in developing treatments in various areas including mental health, autoimmune diseases, and oncology over the past 40 years, emphasized that it will continue to contribute to Korean society by providing innovative medicines and fostering talent.

 

On the 23rd, the company held a press conference celebrating its 40th year of establishment at the Seoul Plaza Hotel.

 

At the event, the company introduced the major achievements it had made in the past 40 years and their significance in each of its therapeutic areas.

 

Managing Director of Janssen Korea Cherry Huang, as well as Chris Hourigan, the Company Group Chairman, Pharmaceuticals, Asia Pacific, Jung-Hee Lee, Chairman of the Board at Yuhan Corp., Professor Sang-Yeol Lee, President of the Korean College of Neuropsychopharmacology, and Young-Shin Lee, CEO of the Korean Research-based Pharmaceutical Industry Association, attended the event.

 

During the four decades, Janssen Korea has provided its innovative drugs to patients in various fields in Korea, including oncology, autoimmune diseases, mental health, and pulmonary hypertension, According to data disclosed by the company, its market share of prescription drugs for autoimmune diseases that are used to treat plaque psoriasis, ulcerative colitis, and Crohn’s disease, has occupied, and is leading the ETC market for autoimmune diseases in Korea.

 

Janssen also strengthened its position in the field of neurology.

 

Its Invega (paliperidone), a treatment for schizophrenia, and Concerta (methylphenidate), a treatment for severe attention deficit hyperactivity disorder (ADHD), were also successfully launched in Korea.

 

In oncology, the company announced its market entry by receiving domestic approval for its CAR-T treatment Carvykti (ciltacabtagene autoleucel) and lung cancer treatment Rybrevant (amivantamab).

 

Janssen Korea is recognized as a global pharmaceutical company that has successfully introduced open innovation to Korea.

 

Janssen purchased the global distribution rights to Yuhan Corporation’s Leclaza (lasertinib) in 2018.

 

Leclaza was developed by Genosco, an American subsidiary of Oscotec, whose technology Yuhan Corp imported to Korea.

 

Since then, Janssen has been evaluating the effectiveness of Leclaza in combination with Rybrevant in lung cancer treatment.

 

The two-drug combination is likely to become a first-line treatment option for non-small cell lung cancer in the future.

 

Jung-Hee Lee, Chairman of Yuhan Corp, who participated that day, highly evaluated Janssen.

 

Yuhan also took the company’s value into consideration when deciding to select Janssen as its global partner and licensed out Leclaza’s technology.

 

Lee said, “I have high respect for Paul Janssen, who founded the company.

 

“Janssen’s philosophy of ‘respect for humanity’ was greatly taken into consideration when choosing a global partner for Leclaza.” Janssen pointed to activities such as fostering domestic talent and providing innovative medicines as measures it will pursue to coexist with Korean society in the future.

 

For this, Huang expressed intentions to cooperate closely with the Korean government, HCPs, and industry officials.

 

Cherry Huang, Managing Director of Janssen Korea, said, “Janssen Korea and will work together with Korea to envision and depict a future in which innovative medicines can be provided to more domestic patients and a future in which we can foster talents that can contribute to the Korean society.

 

I hope we can go beyond the 40 years we have spent together and record another 10 years of history, even 100 years.” Chris Hourigan, the Company Group Chairman, Pharmaceuticals, Asia Pacific, said, “We have been investing in the development of treatments with high unmet needs and for the underprivileged in our society, We are also working closely with the Korean government, HCPs, and industry partners to lead the wave of innovation that can fundamentally tackle the way we deal with disease.”